‘Psychedelics Bills Filed In Four More States As 2023 Reform Efforts Heat Up’ -Marijuana Moment Report
https://www.marijuanamoment.net/psychedelics-bills-filed-in-four-more-states-as-2023-reform-efforts-heat-up/
‘Mexican Senator To File Psychedelics Legalization Bill, With U.S. Congressman Backing International Reform Push’ – Marijuana Moment
https://www.marijuanamoment.net/mexican-senator-to-file-psychedelics-legalization-bill-with-u-s-congressman-backing-international-reform-push/
A Mexican senator announced on Wednesday that she will be introducing a bill
‘New York Governor Signs Bill To Mandate State Legalization Of Schedule I Drugs Like Psilocybin And MDMA If Federal Law Changes’ – Marijuana Moment
https://www.marijuanamoment.net/new-york-governor-signs-bill-to-mandate-state-legalization-of-schedule-i-drugs-like-psilocybin-and-mdma-if-federal-law-changes/
The governor of New York recently signed legislation
‘Lawmakers Are Already Pursuing Psychedelics Legislation In Nearly A Dozen States For 2023: From Connecticut to California, bipartisan lawmakers are signaling strong interest in reforming laws around natural plants and fungi.’ -Marijuana Moment
https://www.marijuanamoment.net/lawmakers-are-already-pursuing-psychedelics-legislation-in-nearly-a-dozen-states-for-2023/
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.
Marijuana Moment Tweets: New York Lawmakers File Psychedelics Legalization Bill For 2023:
https://twitter.com/MarijuanaMoment/status/1608865148336324608
‘California Senator Files Revised Psychedelics Legalization Bill For 2023 – Leaving Out LSD, MDMA And Other Synthetics’ – MarijuanaMoment
https://www.marijuanamoment.net/california-senator-files-revised-psychedelics-legalization-bill-for-2023-leaving-out-lsd-mdma-and-other-synthetics/
A California senator has refiled a bill to legalize possession of
EF Hutton Initiates Coverage On Reunion Neuroscience with Buy Rating, Announces Price Target of $11
EF Hutton analyst Elemer Piros initiates coverage on Reunion Neuroscience (NASDAQ:REUN) with a Buy rating and announces Price Target of $11.
